Literature DB >> 26720284

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

Lecia V Sequist1, Zofia Piotrowska1, Matthew J Niederst1, Rebecca S Heist1, Subba Digumarthy2, Alice T Shaw1, Jeffrey A Engelman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26720284     DOI： 10.1001/jamaoncol.2015.5009

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  20 in total

Review 1.  Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.

Authors:  Roberta Minari; Paola Bordi; Marcello Tiseo
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 2.  Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.

Authors:  Melin J Khandekar; Zofia Piotrowska; Henning Willers; Lecia V Sequist
Journal:  Oncologist       Date:  2018-04-27

3.  Clinical Application of Picodroplet Digital PCR Technology for Rapid Detection of EGFR T790M in Next-Generation Sequencing Libraries and DNA from Limited Tumor Samples.

Authors:  Laetitia Borsu; Julie Intrieri; Linta Thampi; Helena Yu; Gregory Riely; Khedoudja Nafa; Raghu Chandramohan; Marc Ladanyi; Maria E Arcila
Journal:  J Mol Diagn       Date:  2016-09-12       Impact factor: 5.568

4.  A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.

Authors:  Helena A Yu; Alexander Spira; Leora Horn; Jared Weiss; Howard West; Giuseppe Giaccone; Tracey Evans; Ronan J Kelly; Bhardwaj Desai; Andrew Krivoshik; Diarmuid Moran; Srinivasu Poondru; Fei Jie; Kouji Aoyama; Anne Keating; Geoffrey R Oxnard
Journal:  Clin Cancer Res       Date:  2017-09-27       Impact factor: 12.531

5.  Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance.

Authors:  Xu Zhang; Tapan K Maity; Karen E Ross; Yue Qi; Constance M Cultraro; Meriam Bahta; Stephanie Pitts; Meghana Keswani; Shaojian Gao; Khoa Dang P Nguyen; Julie Cowart; Fatos Kirkali; Cathy Wu; Udayan Guha
Journal:  Cancer Res       Date:  2021-03-16       Impact factor: 13.312

Review 6.  New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?

Authors:  Nele Van Der Steen; Chiara Caparello; Christian Rolfo; Patrick Pauwels; Godefridus J Peters; Elisa Giovannetti
Journal:  Onco Targets Ther       Date:  2016-10-06       Impact factor: 4.147

Review 7.  Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options.

Authors:  Jordi Remon; Benjamin Besse
Journal:  ESMO Open       Date:  2016-08-01

Review 8.  Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Bin-Chi Liao; Chia-Chi Lin; Jih-Hsiang Lee; James Chih-Hsin Yang
Journal:  J Biomed Sci       Date:  2016-12-03       Impact factor: 8.410

Review 9.  The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.

Authors:  Xin Gao; Xiuning Le; Daniel B Costa
Journal:  Expert Rev Anticancer Ther       Date:  2016-03-21       Impact factor: 4.512

10.  Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Authors:  Jacob J Chabon; Andrew D Simmons; Alexander F Lovejoy; Mohammad S Esfahani; Aaron M Newman; Henry J Haringsma; David M Kurtz; Henning Stehr; Florian Scherer; Chris A Karlovich; Thomas C Harding; Kathleen A Durkin; Gregory A Otterson; W Thomas Purcell; D Ross Camidge; Jonathan W Goldman; Lecia V Sequist; Zofia Piotrowska; Heather A Wakelee; Joel W Neal; Ash A Alizadeh; Maximilian Diehn
Journal:  Nat Commun       Date:  2016-06-10       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.